BioNexus Gene Lab Corp. (NASDAQ:BGLC – Get Free Report) saw a large increase in short interest during the month of June. As of June 15th, there was short interest totalling 177,900 shares, an increase of 204.1% from the May 31st total of 58,500 shares. Based on an average daily volume of 216,100 shares, the short-interest ratio is presently 0.8 days. Currently, 2.3% of the company’s shares are short sold.
BioNexus Gene Lab Price Performance
Shares of BGLC stock traded up $0.01 on Friday, hitting $0.48. 24,258 shares of the company’s stock traded hands, compared to its average volume of 321,325. BioNexus Gene Lab has a one year low of $0.31 and a one year high of $17.88. The company’s fifty day simple moving average is $0.53 and its 200 day simple moving average is $0.61.
BioNexus Gene Lab (NASDAQ:BGLC – Get Free Report) last announced its quarterly earnings results on Wednesday, May 15th. The company reported ($0.02) earnings per share (EPS) for the quarter. The firm had revenue of $2.38 million during the quarter. BioNexus Gene Lab had a negative return on equity of 30.74% and a negative net margin of 27.24%.
Institutional Investors Weigh In On BioNexus Gene Lab
About BioNexus Gene Lab
BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers.
Further Reading
- Five stocks we like better than BioNexus Gene Lab
- Investing in Construction Stocks
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- What is a Death Cross in Stocks?
- MarketBeat Week in Review – 6/24 – 6/28
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- General Mills Stock Drops After Revenue Miss in Fiscal Q4 2024
Receive News & Ratings for BioNexus Gene Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNexus Gene Lab and related companies with MarketBeat.com's FREE daily email newsletter.